Exercise-based Rehabilitation to Treat Persistent Chemotherapy Induced Peripheral Neuropathy (CIPN) - Trial NCT06405542
Access comprehensive clinical trial information for NCT06405542 through Pure Global AI's free database. This Phase 1 trial is sponsored by University Health Network, Toronto and is currently Recruiting. The study focuses on Chemotherapy-induced Peripheral Neuropathy. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University Health Network, Toronto
Timeline & Enrollment
Phase 1
Apr 25, 2024
Jul 01, 2025
Primary Outcome
Accrual Rate,Retention Rates,Adherence,Intervention Safety
Summary
The goal of this clinical trial is to learn if the EX-CIPN exercise-based intervention is
 feasible, acceptable, and safe in participants with persistent chemotherapy-induced
 peripheral neuropathy (CIPN). It will also give insight on the effectiveness of the exercise
 intervention in treating CIPN symptoms. The main questions it aims to answer are:
 
 - Is EX-CIPN safe, acceptable, and feasible in cancer survivors experiencing persistent
 CIPN?
 
 - Are the study design and methods feasible (recruitment and retention rates, feasibility
 of data collection and procedures)?
 
 Researchers will provide all participants with the exercise-based intervention.
 
 Participants will:
 
 - Complete assessments at baseline, immediately post-intervention, and 3-months
 post-intervention
 
 - Complete a 10-week remote, individualized exercise program
 
 - Receive health coaching calls on weeks 2, 3, 4, 6, and 8 of the intervention
 
 - Wear a FitBit throughout the study to track physical activity and promote behaviour
 change
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06405542
Non-Device Trial